Stock listing

gettex:CBO0 Imunon, Inc. Aktie

German listing (gettex) of Imunon, Inc. · home listing NASDAQ:IMNN

Follow Imunon, Inc. into a list and get an email when it puts out news.

Home listing price · NASDAQ:IMNN

$0.985 USD -0.035 (-3.4%)

Close on Oct 19, 2026 · This listing has no price on 6ix; the price shown is the home listing's, NASDAQ:IMNN

Since Jul 6, 2026 -50.3% · daily closes, Jul 6, 2026 – Oct 19, 2026, adjusted for splits
Day range
$0.980 – $1.020 USDOct 19, 2026
Volume
93,789 sharesOct 19, 2026
Market value
$5.53M USDAt the close on Oct 19, 2026 · price × 5.61M shares outstanding
Imunon, Inc. logo
Ticker
gettex:CBO0
Asset type
Stock
Sector
Health care
Industry
Biotechnology
Exchange
gettex
Currency
EUR

What changed lately

Calls

Replays

  • Imunon (NASDAQ:IMNN) Q2 2026 Earnings Call

    Tue, Aug 11, 2026 · 11:00 AM ET

    Watch Transcript

  • Imunon (NASDAQ:IMNN) Q1 2026 Earnings Call

    Tue, May 12, 2026 · 11:00 AM ET

    Watch Transcript

  • Imunon (NASDAQ:IMNN) Q4 2025 Earnings Call

    Tue, Mar 31, 2026 · 11:00 AM ET

    Watch Transcript

Latest news

IMUNON to Participate in Upcoming Investor Conferences

Oct 8, 2026

IMUNON Converts $1.2 Million of Debt-to-Equity

Sep 29, 2026

IMUNON Reports Independent Data Monitoring Committee Recommends Continued Phase 2 Development of IMNN-001 Following Favorable Safety Review

Sep 22, 2026

IMUNON Enters Cooperative Research and Development Agreement with National Cancer Institute to Advance Clinical Development of IMNN-001

Sep 10, 2026

IMUNON Announces Full Agenda and Speaker Lineup Ahead of 2026 R&D Day Highlighting IMNN-001 Clinical Progress

Sep 9, 2026

IMUNON to Host 2026 R&D Day Highlighting Phase 3 OVATION 3 Trial and the Clinical Potential of IMNN-001

Aug 26, 2026

IMUNON Reports Second Quarter 2026 Financial Results and Provides Business Update

Aug 11, 2026

IMUNON Reports Strong Enrollment Momentum in Phase 3 OVATION 3 Trial of IMNN-001 in Advanced Ovarian Cancer

Jul 30, 2026

IMUNON to Present IMNN-001 Data at Inaugural AACR Conference on Drug Discovery and Development

Jul 23, 2026

IMUNON Reports Positive Phase 2 MRD Clinical Data for IMNN-001, Demonstrating the Successful Overcoming of Historical IL-12 Safety Barriers in Frontline Ovarian Cancer

Jul 21, 2026

All Imunon, Inc. news

Decks

Imunon, Inc. on 6ix

Sector
Health care
Industry
Biotechnology
News releases
30 in the last 12 months · 135 in all · newest Oct 8, 2026 · oldest 2022
Calls
14 calls with a replay · 14 with a transcript · latest Aug 11, 2026
Decks
26 decks · latest Sep 23, 2026

Where Imunon, Inc. is listed

ListingExchangeCountryCurrency
NASDAQ:IMNN · Home listingNASDAQUnited StatesUSD
Lang & Schwarz:A41CNRLang & SchwarzGermanyEUR
LS Exchange:A41CNRLS ExchangeGermanyEUR
Tradegate:CBO0TradegateGermanyEUR
gettex:CBO0 · This pagegettexGermanyEUR
BOATS:IMNNBOATSUnited StatesUSD
Stuttgart:CBO0StuttgartGermanyEUR
Dusseldorf:CBO0DusseldorfGermanyEUR
Frankfurt:CBO0FrankfurtGermanyEUR
LSE:0HUZLSEUnited KingdomUSD
Munich:CBO0MunichGermanyEUR

Log in to ask 6ix AI your own questions about Imunon, Inc.